A study led by researchers at NYU Langone Health and its Perlmutter Cancer Center has highlighted the role of DNA methylation in the increased risk of several cancers, including breast cancer, among rescuers and survivors of the attack on the World Trade Center on Sept. 11, 2001, in New York City.
The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
